Prognosis
Japan Approves Gilead’s Remdesivir to Treat Covid-19 Cases
- Decision comes three days after company applied, NHK says
- U.S. approved drug for emergency use earlier this month
This article is for subscribers only.
Japan on Thursday approved the antiviral drug remdesivir for use against the novel coronavirus, three days after receiving an application from Gilead Sciences Inc., the company said in a statement.
The rapid move by Japan’s usually conservative authorities comes days after the U.S. authorized the drug for emergency use on virus patients. The special approval process used in Japan is reserved for urgent situations, where there is no alternative, and the drug has already been authorized for use overseas.